Back to search results

Pancreatic Cancer Screening for New-Onset or Deteriorating Diabetes

This observational study aims to understand the connection between new-onset or worsening diabetes and pancreatic cancer. You may be eligible if you are at least 50 years old and have been diagnosed with diabetes within the last 12 months. Participants will undergo an MRI/MRCP (Magnetic Resonance Imaging/Magnetic Cholangiopancreatography), a type of imaging scan, at the beginning of the study to look for early signs of pancreatic cancer or precancerous lesions. The study also involves collecting blood samples to help develop a blood test for pancreatic cancer. The main goal is to identify early-stage pancreatic cancer or precursor lesions, with follow-up for up to 3 years. The study's current status is unclear, and it plans to enroll 800 participants.

Study design
This is an observational study, meaning researchers will observe participants without assigning specific treatments. It aims to enroll 800 participants.
What's involved
You would have an MRI/MRCP at the start of the study. You would also complete a five-minute psychological survey and donate blood samples every 6 months for 3 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through study completion, which can be up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03937453

A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus

Recruiting
Not specifiedAges 50+Observational
Nuvance Health
~800 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:MRI/MRCP

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Early Stage Pancreatic Cancer or Precursor Lesions
Measured over Through study completion, up to 3 years

Conditions

Pancreatic Cancer
Pancreatic Neoplasms
Diabetes Mellitus

Explore related trials

Diabetes MellitusPancreatic Carcinoma

Where it's being run

2 sites across 1 states
Connecticut2

Study leadership

  • Richard Frank, MD · PRINCIPAL_INVESTIGATOR · Nuvance Health

Who to contact

Tammy Lo, MSN
[email protected]
203-855-3551
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age of at least 50 years.
DM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c ≥ 6.5% OR
DM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR
Transition from pre-Diabetes to Diabetes Mellitus within the past 12 months characterized by a change in the HbA1c of ≥ 0.5% OR
DM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%. OR
Deteriorating Diabetes: DM with \>2% spike in HbA1c within past 6 months confirmed with repeat testing and NOT associated with weight gain and diabetes medication non-compliance
ECOG Performance Status of 0-1.
No known contraindications to MRI examination or gadolinium contrast.
Willing to undergo MRI and screening for metal implants or metal injury.
Ability to provide informed consent.
Willing to return to study site for all study assessments.

Exclusion

Prior history of pancreatic cancer.
Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.
Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).
Hereditary pancreatitis.
Use of high dose glucocorticoid steroids (at least 20 mg daily of prednisone) within 3 months of diabetes diagnosis or elevation of HbA1c. Lower doses of steroid use as a cause of glucocorticoid-induced diabetes will be made on a case-by-case basis.
Contraindication to MRI examination or gadolinium contrast.
Pregnant or nursing women.
Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.

What this trial measures

  • Early Stage Pancreatic Cancer or Precursor LesionsThrough study completion, up to 3 years

    Determine incidence of pancreatic cancer or precursor lesions in individuals with new-onset diabetes mellitus or deteriorating diabetes